Sorrento Therapeutics, Inc.
CD38 antibody drug conjugate
Last updated:
Abstract:
There is disclosed an antibody drug conjugate (ADC) having an IgG antibody that binds to a CD38 target conjugated at a Cys site in the hinge region of an IgG antibody. There is further disclosed a method for treating multiple myeloma comprising providing an effective amount of a CD38 ADC.
Status:
Grant
Type:
Utility
Filling date:
20 Jun 2018
Issue date:
7 Dec 2021